TP53 and familial pancreatic carcinoma: Although KRAS mutation is frequent in pancreatic cancer, biallelic inactivation of Brca2 promoted chromosomal instability and apoptosis and inhibited carcinogenesis in the presence of Kras activation in murine hereditary pancreatic cancer models with intact Trp53 [13,14].